• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单次口服头孢泊肟酯后血浆和扁桃体组织中头孢泊肟的浓度。

Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil.

作者信息

Gehanno P, Andrews J M, Ichou F, Sultan E, Lenfant B

机构信息

ENT Department, Hôpital Bichat, Paris, France.

出版信息

J Antimicrob Chemother. 1990 Dec;26 Suppl E:47-51. doi: 10.1093/jac/26.suppl_e.47.

DOI:10.1093/jac/26.suppl_e.47
PMID:2292530
Abstract

Seventeen patients undergoing tonsillectomy received cefpodoxime proxetil orally in a dose equivalent to 100 mg cefpodoxime 4, 7 or 12 h before operation. Plasma and tonsillar tissue concentrations of cefpodoxime were assayed by a microbiological method. Tonsillar tissue concentrations after 4 and 7 h were 0.24 and 0.09 mg/kg respectively--being 23% of the plasma concentration. The tonsillar tissue concentration after 12 h was less than 0.06 mg/kg. As the MIC for Streptococcus pyogenes is less than 0.06 mg/l, cefpodoxime proxetil may be of value in acute tonsillitis.

摘要

17例接受扁桃体切除术的患者在手术前4、7或12小时口服头孢泊肟酯,剂量相当于100mg头孢泊肟。采用微生物学方法测定血浆和扁桃体组织中头孢泊肟的浓度。4小时和7小时后的扁桃体组织浓度分别为0.24mg/kg和0.09mg/kg,分别为血浆浓度的23%。12小时后的扁桃体组织浓度低于0.06mg/kg。由于化脓性链球菌的最低抑菌浓度小于0.06mg/l,头孢泊肟酯可能对急性扁桃体炎有价值。

相似文献

1
Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil.单次口服头孢泊肟酯后血浆和扁桃体组织中头孢泊肟的浓度。
J Antimicrob Chemother. 1990 Dec;26 Suppl E:47-51. doi: 10.1093/jac/26.suppl_e.47.
2
Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil.单次口服头孢泊肟酯后血浆和胸腔积液中头孢泊肟的浓度。
J Antimicrob Chemother. 1990 Dec;26 Suppl E:41-6. doi: 10.1093/jac/26.suppl_e.41.
3
Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil.单次口服头孢泊肟酯后血浆及肺组织中头孢泊肟的浓度。
J Antimicrob Chemother. 1990 Dec;26 Suppl E:35-40. doi: 10.1093/jac/26.suppl_e.35.
4
Concentrations of cefpodoxime in plasma, adenoid, and tonsillar tissue after repeated administrations of cefpodoxime proxetil in children.
J Antimicrob Chemother. 1996 Apr;37(4):821-4. doi: 10.1093/jac/37.4.821.
5
Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.口服头孢泊肟酯后头孢泊肟在血浆和皮肤水疱液中的药代动力学。
Antimicrob Agents Chemother. 1990 Jun;34(6):1094-9. doi: 10.1128/AAC.34.6.1094.
6
Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses.头孢泊肟在年轻和老年志愿者单次给药后的药代动力学
J Antimicrob Chemother. 1990 Dec;26 Suppl E:21-8. doi: 10.1093/jac/26.suppl_e.21.
7
Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.头孢泊肟酯的药代动力学及其与抗酸剂和H2受体拮抗剂的相互作用。
Antimicrob Agents Chemother. 1992 Apr;36(4):796-800. doi: 10.1128/AAC.36.4.796.
8
Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil.头孢泊肟酯单剂量及多剂量口服给药后头孢泊肟的药代动力学和耐受性研究。
J Clin Pharmacol. 1991 Dec;31(12):1137-45. doi: 10.1002/j.1552-4604.1991.tb03686.x.
9
Bioavailability of cefpodoxime proxetil with co-administered acetylcysteine.头孢泊肟酯与乙酰半胱氨酸联合给药时的生物利用度。
Arzneimittelforschung. 1996 Apr;46(4):435-8.
10
Cefpodoxime proxetil concentrations in head and neck tissues.头孢泊肟酯在头颈部组织中的浓度。
Infection. 1991 Jan-Feb;19(1):41-3. doi: 10.1007/BF01643757.

引用本文的文献

1
Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.头孢泊肟酯:儿科患者细菌感染治疗应用综述
Paediatr Drugs. 2001;3(2):137-58. doi: 10.2165/00128072-200103020-00006.
2
Clinical and economic considerations in the use of third-generation oral cephalosporins.使用第三代口服头孢菌素的临床和经济考量
Pharmacoeconomics. 1995 May;7(5):416-27. doi: 10.2165/00019053-199507050-00006.
3
Penetration of cefprozil into tonsillar and adenoidal tissues.头孢丙烯在扁桃体和腺样体组织中的渗透情况。
Antimicrob Agents Chemother. 1993 May;37(5):1180-3. doi: 10.1128/AAC.37.5.1180.
4
Pharmacokinetics of anti-infective agents in paediatric patients.抗感染药物在儿科患者中的药代动力学。
Clin Pharmacokinet. 1994 May;26(5):374-95. doi: 10.2165/00003088-199426050-00005.
5
Clinical pharmacokinetics of newer cephalosporins.新型头孢菌素的临床药代动力学
Clin Pharmacokinet. 1995 May;28(5):361-84. doi: 10.2165/00003088-199528050-00003.
6
Cefpodoxime proxetil in upper respiratory tract infections.头孢泊肟酯在上呼吸道感染中的应用
Drugs. 1991;42 Suppl 3:25-33. doi: 10.2165/00003495-199100423-00007.
7
A review of the pharmacokinetics of cefpodoxime proxetil.头孢泊肟酯的药代动力学综述。
Drugs. 1991;42 Suppl 3:13-21. doi: 10.2165/00003495-199100423-00005.
8
Future directions in antimicrobial chemotherapy.抗菌化疗的未来发展方向。
Pharm Weekbl Sci. 1992 Aug 21;14(4A):229-44. doi: 10.1007/BF01962545.
9
Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.头孢泊肟酯。对其抗菌活性、药代动力学特性及治疗潜力的综述。
Drugs. 1992 Nov;44(5):889-917. doi: 10.2165/00003495-199244050-00011.